1996-09--2001-07 PhD in Science: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
1992-09--1996-09 Bachelor of Science: East China Normal University
2006-03~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher, Researcher
2001-09~2006-03 - National Cancer Institute, USA - Postdoctoral Fellow
1996-09~2001-07 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - PhD in Science
1992-09~1996-09 - East China Normal University - Bachelor of Science
Pudong New Area 'Mingzhu Engineer' (2023): City-level, 2023
Research
Pharmacology of Antitumor Drugs
Discovery of Pyrido[2,3- d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment., Linghua Meng, 2024
Second messenger 2'3'-cyclic GMP-AMP (2'3'-cGAMP): the cell autonomous and non-autonomous roles in cancer progression., Linghua Meng, 2024
Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3K inhibitors., Linghua Meng, 2023
Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation, Linghua Meng, 2023
Targeting PI3K overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R, Linghua Meng, 2023
Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy, Linghua Meng, 2022
Repressing MYC by targeting BET synergizes with selective inhibition of PI3K against B cell lymphoma, Linghua Meng, 2022
Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3K inhibitors in esophageal squamous cell carcinoma, Linghua Meng, 2022
SAF-248, a novel PI3K delta-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma, Linghua Meng, 2021
Research progress in multi-targeted anti-tumor natural products, Linghua Meng, 2021
PI3K inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8 + T cells and promoting fatty acid metabolism, Linghua Meng, 2021
Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead., Linghua Meng, 2021
Adaptive resistance to PI3K alpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells, Linghua Meng, 2021
PI3K alpha inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma, Linghua Meng, 2021
Corrigendum to 'Systematic combination screening reveals synergism between rapamycin and sutent against human lung cancer' Cancer Letter 342(2014) 159-166, Linghua Meng, 2020
Progress in molecularly targeted anti-tumor drugs derived from natural products or their derivatives, Linghua Meng, 2020
CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment, Linghua Meng, 2020
Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo2,1-f1,2,4triazine derivatives, Linghua Meng, 2020
Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors., Linghua Meng, 2020
Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening, Linghua Meng, 2020
Systematic combination screening reveals synergism between rapamycin and sutent against human lung cancer (vol 342, pg 159, 2014), Linghua Meng, 2020
Simultaneous inhibition of PI3K alpha and CDK4/6 synergistically suppresses Kras-mutated non-small cell lung cancer, Linghua Meng, 2020
Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho -Naphthaquinone-Containing Natural Product, Linghua Meng, 2019
Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3K alpha inhibition in breast cancer, Linghua Meng, 2019
Design, synthesis, and biological evaluation of thieno3,2-dpyrimidine derivatives as potential simplified phosphatidylinositol 3-kinase alpha inhibitors, Linghua Meng, 2019
Simultaneous inhibition of PI3K alpha and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer, Linghua Meng, 2019
Design, synthesis, and biological activity evaluation of (-)-6-O-desmethylantofine analogues as potent anti-cancer agents, Linghua Meng, 2019
HRAS(G12s) mutant mediates resistance to a PI3K alpha inhibitor CYH33 in esophageal squamous cell carcinomas, Linghua Meng, 2019
Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA(H1047R) accompanied with pro-tumorigenic secretome, Linghua Meng, 2019
Simultaneous inhibition of PI3K and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer, Linghua Meng, 2019
PI3K alpha inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment, Linghua Meng, 2019
Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer, Linghua Meng, 2019
Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K alpha-selective inhibitor CYH33 in breast cancer, Linghua Meng, 2018
Discovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo2,1-f1,2,4triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors, Linghua Meng, 2018
Oncogene-induced senescence: a double edged sword in cancer, Linghua Meng, 2018
The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8, Linghua Meng, 2018
Oncogene-induced senescence: a double edged sword in cancer, Linghua Meng, 2018
Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf V600E inhibitors, Linghua Meng, 2017
Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K alpha-selective Inhibitors in Breast Cancer, Linghua Meng, 2017
Discovery of a Novel Series of 7-AzaindoleScaffold Derivatives as PI3K Inhibitors with Potent Activity, Linghua Meng, 2017
6-OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression, Linghua Meng, 2017
New Insights into PI3K Inhibitor Design using X-ray Structures of PI3K alpha Complexed with a Potent Lead Compound, Linghua Meng, 2017
Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond, Linghua Meng, 2015
Toward rapamycin analog (rapalog)-based precision cancer therapy, Linghua Meng, 2015
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies, Linghua Meng, 2015
Identification of a Non-Gatekeeper Hotspot for Drug ResistantMutations in mTOR Kinase, Linghua Meng, 2015
Design, synthesis and biological evaluation of acylhydrazone derivatives as PI3K inhibitors, Linghua Meng, 2015
新娃儿藤碱类似物抗肿瘤作用机制研究, Linghua Meng, 2015
Toward rapamycin analog (rapalog)-based precision cancer therapy, Linghua Meng, 2015
DW09849, a Selective Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Prevents PI3K Signaling and Preferentially Inhibits Proliferation of Cells Containing the Oncogenic Mutation p110 alpha (
Area of Focus
Angiogenesis | Tumor | Vascular | Drug Development | Mechanisms | Antitumor | Therapy | Pharmacology | Molecular Biology | Clinical Research
Area of Focus
Anti-Infection | Antitumor | Antithrombotic | Drug Development | Small Molecules | Innovative Drugs | Research | Pharmaceuticals | Medicinal Chemistry | Clinical Research
